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Parkinson’s disease (PD) is a common neurodegenerative condition affecting more than 8 
million people worldwide. Although, the majority of PD cases are sporadic in nature, there 
are a growing number of monogenic mutations identified to cause PD in a highly penetrant 
manner. Many of these familial mutations give rise to a condition that is clinically and 
neuropathologically similar, if not identical, to sporadic PD. Mutations in genes such as 
SNCA cause PD in an autosomal dominant manner and patients have motor and non-
motor symptoms that are typical for sporadic PD. With the advent of reprogramming 
technology it is now possible to capture these mutations in induced pluripotent stem cells 
(iPSCs) to establish models of PD in a dish. There are multiple neuronal subtypes affected 
in PD including the midbrain dopaminergic (mDA) neurons of the substantia nigra. Robust 
neuronal differentiation into mDA or other relevant neural cell types are critical to 
accurately model the disease and ensure the findings are relevant to understanding the 
disease process. Another challenge for establishing accurate models of PD is being met 
by the generation of isogenic control iPSC lines with precise correction of mutations using 
advanced gene editing technology. The contributions of ageing and environmental factors 
present further challenges to this field, but significant progress is being made in these 
areas to establish highly relevant and robust models of PD. These human neuronal 
models, used in conjunction with other model systems, will vastly improve our 
understanding of the early stages of the PD, which will be key to identifying disease-
modifying and preventative treatments. 
 
Familial Parkinson’s disease 
 
William Gowers was the first to report that Parkinson’s may be hereditary. He noted that 
although less than 15% of his patients had a family history of PD, but when it did exist, 
multiple family members were affected prompting him to state, “hereditary influence may 
be powerful” (1). In 1997 the first genetic cause of PD was identified to be a G209A 
mutation in the SNCA gene, encoding a relatively unknown protein at the time α-synuclein 
(2). This resulted in a substitution of alanine to threonine at position 53 of the protein 
(A53T). The mode of inheritance was autosomal dominant and the mutation appeared to 
be a fully penetrant cause of disease in the affected families (2). The significance of this 
important genetic discovery was further enhanced with a report demonstrating that 
aggregated α-synuclein was a major component of Lewy bodies, the pathological hallmark 
of sporadic PD (3). Since then five additional mutations in the SNCA gene have been 
identified to cause familial PD. Each mutation caused a single amino acid substition to α-
synuclein: A30P, E46K, H50Q, G51D, and A53E (4-10). In addition to point mutations, 
duplication or triplication of a region within chromosome 4q21 encompassing the SNCA 
gene locus, were identified to cause autosomal dominant PD (11-13). The size of the 
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duplication or triplication region differs between families suggestive of de novo 
chromosomal events (14). The dose of α-synuclein over-expression is positively correlated 
with clinical severity, with SNCA duplication patients exhibiting a later age of onset and a 
slower rate of progression than SNCA triplication patients (14,15). 
 
The most common cause of familial PD is due to mutations in the gene encoding LRRK2 
(leucine-rich repeat kinase 2) (16,17). This is a large multifunctional protein and familial 
mutations are thought to increase its kinase activity (18). The LRRK2 mutations are 
autosomal dominant with age-dependent penetrance. Patients with LRRK2 mutations 
have Levodopa-responsive PD and Lewy body pathology that is similar to sporadic 
Parkinson’s. The heterogeneity of LRRK2 genetics and its implications for therapeutic 
approaches to PD have been reviewed (19). In the last 20 years, at least 12 additional 
genes have been identified to cause familial PD when mutated (20). Some of the 
mutations cause Lewy body-positive PD with a disease course and progression similar to 
sporadic PD, while other mutations, including the majority of autosomal recessive 
mutations, cause an atypical PD that is often negative for Lewy body formation (21). 
 
Reprogramming and neuronal differentiation 
 
The discovery that adult cells can be reversed in developmental time to an embryonic 
state by the over-expression of a handful of transcription factors has been transformative 
(22,23). This so-called reprogramming technology has provided a unique and 
unprecedented opportunity to model human conditions with disease-relevant cell types. 
Although patients with idiopathic disease have been studied with reprogramming, this 
technology is most powerful when applied to patients with a monogenic or complex 
genetic cause to their condition. The methods to reprogram somatic cells, such as blood or 
skin, into induced pluripotent stem cells (iPSCs) have been extensively reviewed (24,25). 
The current and most common methods for human iPSC generation use non-integrating 
reprogramming technologies, such as episomes, synthetic mRNAs or Sendai virus (26-
28). There have been thousands of human iPSC lines generated worldwide over the last 
10 years, and it is now clear that not all iPSC lines are created equal. The issues of partial 
reprogramming or epigenetic memory of the starting somatic cell type may hamper any 
downstream disease modeling efforts. There are numerous quality-control measures that 
can be applied to measure the quality of the iPSCs produced. Morphology and expression 
of pluripotent markers, such as NANOG, are useful as a first level of screening, but these 
measures cannot distinguish good from poor iPSC. However, one of the most robust 
measures of iPSC quality is transcriptomic analysis. The global transcriptional signature of 
a high-quality iPSC line should be within the transcriptional ‘space’ of bona fide human 
embryonic stem cells (hESCs). This can be accomplished with bioinformatics tools such as 
PluriTest (29), or by principle component analysis comparing iPSC transcriptome data with 
publicly-available data on hESCs (30). If the RNA expression signature of an iPSC line 
does not cluster with hESCs, it suggests either incomplete reprogramming or the cell line 
has novel properties that are outside the normal phenotype of a human pluripotent stem 
cell line. One of these properties could be a reduced ability to differentiate into the three 
germ layers, which will hamper any downstream disease modeling. Variable differentiation 
potency of iPSC lines, even from the same individual, have been observed in studies that 
use sufficiently large amounts of iPSC lines (31,32). The teratoma assay is commonly 
used to characterize novel iPSC lines, but low-quality iPSCs with an aberrant 
transcriptional signature and poor differentiation capabilities perform well in this assay. The 
ability to form teratomas is not a reliable method to discriminate between high and low 
quality iPSCs. 
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 The other important aspect of reprogramming to be concerned with is the genetic 
integrity of the established iPSC lines. Since human iPSC generation is usually a clonal 
process from an adult cell type, there are many opportunities mutations or chromosomal 
aberrations to occur de novo, or be expanded from the somatic cell starting material. 
Whole genome sequencing of a large collection of iPSC lines demonstrated that an 
average of 6 coding mutations occur during reprogramming (33), and whole genome SNP 
arrays showed that novel copy number variations arise in iPSCs with high frequency (34). 
Large chromosomal abnormalities are also fairly common during reprogramming and 
subsequent expansion of cells with over 20% of published iPSC lines harboring a 
karyotypic defect (35). These findings highlight the need for multiple iPSC lines and 
mutation-corrected isogenic control lines for each genetic condition under investigation. 
 Once a collection of disease and control iPSC lines have been established and 
validated, the next stage is to differentiate them into specific cell types relevant to the 
condition being modeled. For PD this is most often midbrain dopaminergic (mDA) neurons. 
However, it is equally valid to differentiate iPSCs into other neuronal cell types affected in 
PD, such as enteric neurons, olfactory neurons, and cortical neurons. The rate-limiting 
step is the availability and robustness of protocols to produce these various cell types. 
Cortical neurons can be efficiently differentiated from human iPSCs in the presence of 
inhibitors of the two major branches of the SMAD signaling pathway – (i) BMP and (ii) 
TFGβ/activin (36). This so-called dual SMAD inhibition protocol results in the production of 
multiple classes of cortical neurons representative of all the cortical layers (37). These 
neurons would be suitable for investigating the dementia aspects of PD and for modeling 
dementia with Lewy bodies. 
 Although many neuronal systems are affected in PD, it is the mDA neurons of the 
substantia nigra pars compacta (SNpc) that are most acutely lost. Protocols to produce 
mDA neurons from pluripotent stem cells were relatively inefficient until the focus shifted to 
floor plate tissue. The embryological origin of nigral dopaminergic neurons is the floor plate 
of the midbrain. While this signaling centre in the ventral neural tube would normally 
degenerate in the spinal cord and hindbrain, it survives in the midbrain and gives rise to 
mDA neurons (38). Based on this knowledge from embryo development, human floor plate 
cells were efficiently differentiated from hESCs using dual SMAD inhibition and early, 
strong activation of the sonic hedgehog (SHH) pathway (39). These cells were similar to 
diencephalic floor plate, but could be caudalized by factors, such as WNTs and retinoic 
acid. This protocol was refined with the use of the GSK3β inhibitor, CHIR99021 (CHIR), to 
activate the WNT signaling pathway to produce midbrain floor plate (40). This floor plate 
tissue could be further differentiated into mDA neurons and matured in vitro to express 
markers of the SNpc, such as GIRK2, and exhibit electrophysiological properties similar to 
SNpc neurons in vivo. Furthermore, when mDA progenitors from this floor plate protocol 
were grafted into 6-hydroxy-dopamine (6-OHDA) lesioned mice and rats, the cells survived 
and matured into functional mDA neurons, and rescued the dopamine deficits in these 
animal models (40). Tuning the level of CHIR is critical to producing the desired mDA 
neuronal cell type. Too much CHIR and the cells become hindbrain neurons, and too little 
CHIR the neurons take on more rostral fates (41). Most of these protocols have been 
optimized with one or two hESC lines, and transfer to other cell lines often requires 
adjustments to the protocol, or in extreme cases the protocol fails to work with some cell 
lines (31,42). It is important for disease modeling to be aware of variable differentiation 
propensity of iPSC lines, and to control for this by identifying, and quantifying, the neuronal 
and non-neuronal cell types in each batch of differentiated cells (Figure 1A). Optimization 
of differentiation conditions for each iPSC line under investigation may be necessary. 
 
iPSCs with α-synuclein mutations to model Parkinson’s 
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The first report of familial PD iPSCs with an α-synuclein mutation was from Rudolf 
Jaenisch’s laboratory. They established iPSC lines from a skin biopsy from a patient in the 
Contursi kindred harboring the A53T SNCA mutation (43). Furthermore, they used zinc 
finger nucleases to repair the point mutation and establish isogenic control lines. They also 
introduced this mutation, and separately the E46K SNCA mutation into wild-type hESCs to 
establish additional sets of disease and control isogenic cell lines (43). They demonstrated 
that the cell lines could differentiate into tyrosine hydroxylase (TH)-positive dopaminergic 
neurons, but phenotypic analysis was not undertaken (Table 1).  
 The second reported set of iPSCs with an α-synuclein mutation was from a female 
patient of the Iowa kindred harboring a triplication of the SNCA locus. Devine and 
colleagues established 30 iPSC lines from the alpha-synuclein triplication (AST) patient, 
and 10 iPSC lines from her unaffected daughter (NAS – for normal alpha-synuclein) (42). 
Due to the large number of cell lines produced, this was one of the first publications to 
observe variability in differentiation propensity between iPSC lines derived from the same 
individual.  When differentiation efficiency was controlled for, a doubling of SNCA mRNA 
and α-synuclein protein was observed in AST mDA neurons compared to control neurons, 
as predicted from the genotypes. While verifying that the triplication mutation was present, 
it was confirmed that the multiplication region on chromosome 4q22 was very large indeed 
(>1.9 Mb), and encompassed at least 9 coding genes including SNCA (14). Gene 
expression profiling revealed that all genes in the triplication region, including α-synuclein, 
were over-expressed in AST mDA neurons when compared to control neurons. There is 
another family in the US, the Lister kindred, which harbors a much smaller triplication 
region that encompasses SNCA, and one other gene, MMRN1, but they have the same 
clinical and pathological features as the Iowa kindred (14). These observations, as well as 
data from duplication SNCA families, strongly implicate increased α-synuclein expression 
as the cause of familial PD in these families. However, the over-expression of multiple 
proteins in the disease versus control neurons will complicate the interpretation of results 
when performing phenotypic analysis in iPSC-derived neurons in vitro. Isogenic control 
lines could be generated by precisely deleting two of the four SNCA alleles, while leaving 
the rest of the triplication region intact (Figure 1B). This is expected to reduce the 
expression of α-synuclein to wild-type levels, while leaving the other linked genes in the 
triplication over-expressed. Phenotypes specifically due to elevated α-synuclein 
expression should be rescued in such isogenic control lines. 
 Another set of triplication SNCA iPSC lines were established from a male member 
of the Iowa kindred and control iPSCs from his unaffected sister (44). Multiple iPSC lines 
were differentiated into mDA neurons using a rosette-based protocol (45). They also 
observed elevated expression of SNCA mRNA and α-synuclein protein in triplication 
SNCA neurons, as well as increased expression of a select set of oxidative stress genes 
and aggregation-related genes, HMOX2, DNAJA1, and HSPB1 (Table 1). Furthermore, 
triplication SNCA neurons had increased sensitivity to hydrogen peroxide treatment (46). 
 Susan Lindquist and colleagues used a yeast model of synucleinopathy to identify 
vesicular trafficking defects and nitrosative stress as major phenotypic outcomes of 
aggregated α-synuclein protein (47). These insights were used to guide phenotypic studies 
in A53T SNCA and triplication SNCA iPSC models. They observed significant levels of 
nitrosative stress in A53T SNCA cortical neurons, which was absent in isogenic, mutation-
corrected control neurons (48). Endoplasmic reticulum (ER) stress was also observed in 
A53T and triplication SNCA neurons with the accumulation of ER-associated degradation 
(ERAD) substrates (Table 1). This phenotype was not observed in isogenic control 
neurons or in hESC-derived cortical neurons. Furthermore, drugs identified in a yeast 
screen, such as NAB2, to alleviate phenotypes due to α-synuclein aggregation, also 
reduce levels of ER and nitrosative stress in human A53T SNCA neurons underscoring the 
conserved mechanisms of toxicity for this protein (48). 
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 Flierl and colleagues investigated two triplication SNCA iPSC lines from a male 
member of the Iowa kindred, and a control iPSC cell line from his unaffected sister (49). 
They also established an SNCA knock-down line with some reduction of α-synuclein in the 
triplication SNCA line. All of the phenotypic analysis was performed in neural precursor 
cells (NPCs) established by the dual SMAD inhibition method. Phenotypes included 
reduced S-phase, increased sensitivity to the toxins rotenone and paraquat, and increased 
reactive oxygen species production (Table 1). It is unclear if one or both of the triplication 
SNCA iPSC lines exhibited these phenotypes, but it is compelling to see that knock-down 
of SNCA expression in NPCs by RNAi rescued a number of the defects (49). A 
subsequent publication using the same set of iPSC lines observed a defect in neuronal 
differentiation and maturation of the triplication SNCA NPCs (50).  Knock-down of SNCA 
expression partially rescued the differentiation defect in one of the two iPSC lines. The 
small number of iPSC lines used in this study, and the lack of a differentiation defect in 
other studies on triplication SNCA iPSC lines suggest the observed developmental 
phenotype is likely due to clonal variation in differentiation propensity. 
 Lin and colleagues examined a total of 12 iPSC lines, including a triplication SNCA 
line, several LRRK2 mutant lines, and a number of control lines, and found no significant 
difference in efficiency of mDA differentiation (51). However, they did observe significant 
accumulation of phospho-Ser-129-α-synuclein (pSer129-αSyn), a pathological mark, in 
triplication SNCA neurons, but not in LRRK2 mutant neurons (51). Similar to other studies, 
they also observed an increased sensitivity of the PD neurons to toxins, such as 6-OHDA 
and paraquat. RNAseq revealed altered expression in genes involved in synaptic signaling 
transmission, as well as genes involved in alternative splicing, the latter likely due to the 
up-regulation of RBFOX1 (51). 
 Most recently Rebecca Matsas and colleagues reported defects in synaptic 
connectivity and axonal pathology in neurons differentiated from multiple A53T SNCA 
iPSC lines established from two patients (52). Similar to the triplication SNCA neurons, 
they detected pSer129-αSyn structures in A53T SNCA neurons, but not in control 
neurons. They also identified Thioflavin S-positive aggregates, α-synuclein-positive 
structures within inclusion bodies and reduction of neurite quantity and length. RNA 
expression profiling identified a preponderance of differentially expressed transcripts 
encoding for pre-synaptic and post-synaptic proteins (52). In the absence of isogenic 
control iPSC lines, they used small molecule modulators of α-synuclein aggregation, such 
as NPT100-18A. This is a cyclic peptidomimetic compound that was shown to reduce α-
synuclein accumulation and phosphorylation in transgenic mice and it can rescue motor 
deficits in multiple PD rodent models (53). Treatment of A53T SNCA iPSC-derived 
neurons with NPT100-18A significantly rescued the neurite defects and reduced the 




Numerous studies on iPSCs harboring the A53T SNCA mutation or triplication of the wild-
type SNCA gene are now published (42-44,48-52). The over-expression of SNCA mRNA 
and α-synuclein protein is a common observation across multiple studies on triplication 
SNCA iPSCs, as well as increased sensitivity of oxidative stress, which may be indicative 
of mitochondrial dysfunction. The early pathological PD marker, pSer129-αSyn, was 
investigated and identified in both triplication and A53T SNCA neurons (51,52). ER stress 
and alterations at the synapse were also observed and in agreement with other cell and 
rodent models of α-synuclein dysfunction. Gene expression profiling also pointed to the 
synapse as an early target of α-synuclein dysfunction. 
 Modeling synucleinopathies with iPSC-derived neurons is challenging and requires 
an appreciation of the clonal variation of iPSC lines and of the heterogeneous and variable 
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outcome of differentiation protocols. With the advent of CRISPR/Cas9 genome editing it is 
now feasible to establish isogenic control lines to reduce problems of genetic background 
as well as clonal variation. Furthermore, it is now possible to simultaneously generate 
mutation-corrected isogenic control iPSCs lines during the initial reprogramming process 
(54). This not only saves time, but also ensures that the mutant and isogenic controls lines 
are at a similar passage and epigenetic state. Mutations that cause late-onset 
neurodegenerative conditions, such as PD, are not expected to cause developmental 
defects. Therefore, differentiated populations should be quantitatively characterized for the 
presence of desired cell types to ensure the iPSC-derived neurons are of the same identity 
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Figure 1. Modeling Parkinson’s with mutant and isogenic control iPSC lines. 
(A) Skin fibroblasts (or blood) from a familial Parkinson’s patient is used to generate iPSC 
lines using a non-integrating method of reprogramming. Monogenic mutations can then be 
corrected by CRISPR/Cas9 technology to produce isogenic control iPSC lines. The mutant 
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and control iPSC lines are then differentiated into neural precursor cells (NPCs), and 
matured into neurons using optimized protocols. It is important to confirm differentiation 
efficiency is relatively similar for the different iPSC lines. (B) The triplication SNCA 
mutation that causes autosomal dominant PD is located on the long arm of chromosome 
4. The triplication region is greater than 1.5 Mb in size and encompasses multiple coding 
genes in addition to SNCA. These genes are MMRN1, GPRIN3, TIGD2, FAM13A, 
NAP1L5, PIGY, PYURF, HERC3, and HERC5. In order to generate isogenic control iPSC 
lines, the first coding exon of the SNCA gene (exon 2) can be deleted by CRISPR/Cas9 
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